|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 754.14 USD | -0.63% |
|
-2.88% | -2.30% |
| 14/01 | Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs | MT |
| 13/01 | Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $885 From $870, Maintains Buy Rating | MT |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 50,990 | 66,029 | 77,057 | 93,403 | 76,639 | 77,864 | 77,864 | - |
| Change | - | 29.49% | 16.7% | 21.21% | -17.95% | 1.6% | 0% | - |
| Enterprise Value (EV) 1 | 50,098 | 56,196 | 77,057 | 84,542 | 70,331 | 71,332 | 69,504 | 67,937 |
| Change | - | 12.17% | 37.12% | 9.71% | -16.81% | 1.42% | -2.56% | -2.25% |
| P/E ratio | 15.8x | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 19.2x | 15.8x |
| PBR | 4.71x | 3.56x | 3.41x | 3.64x | 2.62x | 2.44x | 2.2x | 1.95x |
| PEG | - | 0x | -0.4x | -2.8x | 1.8x | 2.85x | -6.09x | 0.7x |
| Capitalization / Revenue | 6x | 4.11x | 6.33x | 7.12x | 5.4x | 5.48x | 5.08x | 4.64x |
| EV / Revenue | 5.9x | 3.5x | 6.33x | 6.45x | 4.95x | 5.02x | 4.53x | 4.05x |
| EV / EBITDA | 11.8x | 5.71x | 12.7x | 15.2x | 12.3x | 12.7x | 11.6x | 9.52x |
| EV / EBIT | 14x | 6.28x | 13.5x | 16.5x | 13.5x | 15.2x | 13.4x | 10.7x |
| EV / FCF | 25x | 8.61x | 17.4x | 21.8x | 19.2x | 14.1x | 15.5x | 13.3x |
| FCF Yield | 4% | 11.6% | 5.74% | 4.58% | 5.21% | 7.09% | 6.45% | 7.52% |
| Dividend per Share 2 | - | - | - | - | - | 3.672 | 3.906 | 4.471 |
| Rate of return | - | - | - | - | - | 0.48% | 0.51% | 0.59% |
| EPS 2 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 40.84 | 39.56 | 48.03 |
| Distribution rate | - | - | - | - | - | 8.99% | 9.87% | 9.31% |
| Net sales 1 | 8,497 | 16,072 | 12,173 | 13,117 | 14,202 | 14,213 | 15,332 | 16,774 |
| EBITDA 1 | 4,244 | 9,835 | 6,060 | 5,547 | 5,695 | 5,601 | 6,004 | 7,138 |
| EBIT 1 | 3,577 | 8,947 | 5,719 | 5,126 | 5,212 | 4,684 | 5,197 | 6,356 |
| Net income 1 | 3,513 | 8,075 | 4,338 | 3,954 | 4,413 | 4,316 | 4,192 | 4,981 |
| Net Debt 1 | -891.3 | -9,833 | - | -8,862 | -6,308 | -6,532 | -8,360 | -9,926 |
| Reference price 2 | 483.11 | 631.52 | 721.49 | 878.29 | 712.33 | 758.91 | 758.91 | 758.91 |
| Nbr of stocks (in thousands) | 1,05,544 | 1,04,556 | 1,06,802 | 1,06,347 | 1,07,590 | 1,02,599 | 1,02,599 | - |
| Announcement Date | 05/02/21 | 04/02/22 | 03/02/23 | 02/02/24 | 04/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.58x | 5.02x | 12.74x | 0.48% | 7.79TCr | |
| 57.48x | 15.2x | 32.61x | -.--% | 5.98TCr | |
| 22.12x | 4.04x | 11.74x | 2.67% | 5.58TCr | |
| 42.64x | 6.72x | 21.9x | 0.56% | 5.62TCr | |
| 17.18x | 2.84x | 8.94x | -.--% | 2.62TCr | |
| 16.7x | 3.28x | 9.85x | -.--% | 2.03TCr | |
| 81.88x | 9.8x | 88.37x | -.--% | 1.99TCr | |
| 351.99x | 106.79x | 173.52x | - | 1.73TCr | |
| -23.12x | 33.14x | -33.85x | -.--% | 1.52TCr | |
| Average | 65.05x | 20.76x | 36.20x | 0.46% | 3.87TCr | |
| Weighted average by Cap. | 47.81x | 13.17x | 27.26x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- REGN Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition